<DOC>
	<DOC>NCT02580994</DOC>
	<brief_summary>This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab (MK-3475) in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.</brief_summary>
	<brief_title>Pembrolizumab in Untreated Extensive SCLC</brief_title>
	<detailed_description>This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab (MK-3475) in combination with standard chemotherapy in ED-SCLC. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the informed consent, and then centrally randomized 1:1 to the experimental arm (Arm A) and the control arm (Arm B). Cross-over at the time of disease progression will be allowed for arm B only.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically or cytologically confirmed SCLC Extended disease according to the criteria of the Veteran's Administration Lung Cancer Group (VALG) No prior systemic therapy for SCLC Measurable disease Previous palliative brain radiotherapy is allowed if terminated at least 3 weeks before treatment start Partial or complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 after 2 cycles of any platinumbased induction chemotherapy regimen Performance Status 34 No adequate organ function Less than 3 month life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>phase II</keyword>
	<keyword>randomized</keyword>
	<keyword>pembrolizumab</keyword>
</DOC>